Teva, mAbxience ink global licensing agreement for oncology biosimilar candidate
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries, and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in global oncology care.
The licensing agreement covers multiple global markets, including Europe and the United States, signaling a major step in mAbxience’s global expansion strategy, and supports a key element of Teva’s Pivot to Growth strategy. Announced in 2023, the strategy will expand its biosimilar pipeline through business development and partnerships.
Under the terms of the licensing agreement, mAbxience will leverage its expertise in biosimilar development and its Good Manufacturing Practice-approved facilities in Spain and Argentina to develop and produce the biosimilar product. Teva will lead the regulatory processes and commercialization in the designated regions to ensure access to a broader patient population.
[Read more: Teva rolls out generic Nexavar tablets]
“Teva is pleased to form this strategic alliance with mAbxience, who share our commitment to accelerate the delivery of impactful medicines to patients worldwide,” said Angus Grant, executive vice president of business development at Teva. “This collaboration reflects Teva’s ideal strategic partnership model to optimize development costs, mitigate risk and leverage our extensive commercial capabilities.”
“Partnering with Teva not only reinforces mAbxience's position as a global biosimilar company but also aligns with our mission to deliver high-quality, affordable healthcare solutions across continents,” said Jurgen Van Broeck, global commercial director of mAbxience. “This agreement will assist healthcare systems in reducing costs, ensuring the provision of these vital cancer treatments to all patients who require them.”
[Read more: Teva intends to divest API business]